Wyeth

Basf Aktiengesellschaft

Jacobus Pharmaceutical Company, Inc.

American Cyanamid Company

Jacobus Pharmaceuticals Company, Inc.

Gavin David Heffernan

Casey Cameron McComas

Michael Anthony Marella

Andrew Fensome

Thomas Joseph Commons

Ronald Charles Bernotas

Edward George Melenski

Richard Dale Coghlan

Michael Byron Webb

Richard Page Woodworth, Jr

Amedeo A Failli

Waldemar F Pfrengle

Dominick Anthony Quagliato

Klaus-Juergen Pees

David Penman Jacobus

Hong-Ming Shieh

Wenyi Zhao

Emily S Shen

Eugene John Trybulski

Peter J Wepplo

Michael A Guaciaro

Patrick Michael Andrae

Michael Vernie Cossette

Richard Anthony Rampulla

Albert Jean Robichaud

Gary Paul Stack

Venkataraman Kameswaran

Puwen Zhang

Arthur Attilio Santilli

Robert E Diehl

Eugene Anthony Terefenko

Paige Erin Mahaney

Robert E McDevitt

Keith Douglas Barnes

Stephen Todd Cohn

Kurt William Saionz

Mark C Manfredi

Jonathan Laird Gross

David Allen Hunt

Dahui Zhou

Joseph Peter Sabatucci

An Thien Vu

Marianne Carlsen

Charles Malcolm Langevine

Sergio I Alvarado

Fei Ye

Yanfang Li

Hong Gao

Gregory J Haley

Susan Christman Croce

Callain Younghee Kim

James Joseph Fiordeliso

Gary Allen Meier

Billy Gene Bullock

Gregory Jay Haley

The present invention relates to antimalarial compounds and their use against protozoa of the genus, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Heteroaryl derivatives and uses thereof

The present invention relates to antimalarial compounds and their use against protozoa of the genusincluding drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.

Aryl derivatives and uses thereof

This invention provides pyrrolobenzodiazepine arylcarboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists, as well as pharmaceutical compositions and methods of treatment utilizing these compounds. 

Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists

The invention provides compounds of formula or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, and B are as defined in the accompanying specification. Methods of making such compounds are also provided.

Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2). 

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

Compounds of the following structure are described: wherein R-R, R, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Imidazolidin-2-one derivatives useful as PR modulators

Compounds of the following structure are described: wherein R-R, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazolidine derivatives as PR modulators

The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.

Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors

Compounds of the following structure are described: wherein R, R, R, R, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R-R, R, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Tricyclic oxazolidone derivatives useful as PR modulators

Compounds of the following structure are described: wherein R-R, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazinan-2-one derivatives useful as PR modulators

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Phenylaminopropanol derivatives and methods of their use

Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R, R, R, R, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Chromane and chromene derivatives and uses thereof

Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines

Growing community of inventors

Florence, NJ, United States of America

Gavin David Heffernan